MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on September 11, 2006; DOI: 10.1124/mol.106.029298

0026-895X/06/7006-2037-2044$20.00
Mol Pharmacol 70:2037-2044, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.029298v1
70/6/2037    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kishi, M.
Right arrow Articles by Steinbach, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kishi, M.
Right arrow Articles by Steinbach, J. H.

Role of the Agonist Binding Site in Up-Regulation of Neuronal Nicotinic {alpha}4beta2 Receptors

Masashi Kishi, and Joe Henry Steinbach

Department of Anesthesiology, Washington University School of Medicine, Saint Louis, Missouri

Long-term exposure to nicotinic ligands results in up-regulation of neuronal nicotinic {alpha}4beta2 receptors in the brain and in heterologous expression systems. Up-regulation can be produced by a variety of drugs, including nicotinic agonists and competitive antagonists, but previous studies have indicated that the signal for up-regulation does not reflect a traditional nicotinic pharmacology, and the initial steps in signal transduction are not clear. We examined the signal for up-regulation and the possible involvement of the nicotine binding site in signal reception using mutated subunits transiently expressed in human embryonic kidney 293 cells. The data indicate that receptor activation and desensitization are not part of the signaling pathway. However, mutations to residues in the binding site can affect up-regulation. These results provide evidence that the binding site is directly involved in receiving the signal for up-regulation.

Received July 25, 2006; accepted September 11, 2006

Address correspondence to: Dr. Joe Henry Steinbach, Department of Anesthesiology, Washington University School of Medicine, 660 South Euclid Avenue, Saint Louis MO 63110. E-mail jhs{at}morpheus.wustl.edu




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Walsh, A. P. Govind, R. Mastro, J. C. Hoda, D. Bertrand, Y. Vallejo, and W. N. Green
Up-regulation of Nicotinic Receptors by Nicotine Varies with Receptor Subtype
J. Biol. Chem., March 7, 2008; 283(10): 6022 - 6032.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. C. Gahring, A. V. Osborne-Hereford, G. A. Vasquez-Opazo, and S. W. Rogers
Tumor Necrosis Factor {alpha} Enhances Nicotinic Receptor Up-regulation via a p38MAPK-dependent Pathway
J. Biol. Chem., January 11, 2008; 283(2): 693 - 699.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics